Biopharmaceutical News and Research

RSS

NeuroTrauma Sciences and Henry Ford join hands to advance exosome technology

NeuroTrauma Sciences, LLC, a biopharmaceutical company, and Henry Ford Health System, a non-profit organization, today announce that a newly-formed subsidiary of NTS has entered into multi-year Sponsored Research and License Agreements.

16 Jul 2018

Aeras announces publication of Phase 2 results of two TB vaccines

Aeras, a nonprofit organization dedicated to developing vaccines against tuberculosis (TB), today announced the publication of the full results from a Phase 2, randomized, controlled clinical trial of two TB vaccines-- the currently available BCG vaccine and an investigational vaccine, H4:IC31--in the New England Journal of Medicine (NEJM).

12 Jul 2018

Aurinia’s Phase 2 trial evaluates voclosporin ophthalmic solution for treating dry eye syndrome

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the global immunology market, today announced the initiation of its Phase 2 trial evaluating voclosporin ophthalmic solution (VOS) for the treatment of dry eye syndrome (DES).

12 Jul 2018

New clinical trial to evaluate virotherapy and immunotherapy combination for ovarian, colorectal cancers

Ludwig Cancer Research and the Cancer Research Institute announce the initiation of a clinical trial to evaluate the combination of ONCOS-102, an experimental anti-tumor virotherapy, with the checkpoint blockade antibody IMFINZI (durvalumab) for advanced ovarian and colorectal cancers.

12 Jul 2018

Sartorius Stedim Biotech and Penn State partner to advance teaching, research in biotechnology

Sartorius Stedim Biotech and Penn State University have entered into a collaborative partnership to advance multidisciplinary teaching and research in biotechnology. This long-term relationship will support the education and preparation of the next generation of biotechnology leaders.

From Sartorius 10 Jul 2018

CTI BioPharma announces Phase III results of PIXUVRI combined with rituximab in aggressive B-cell NHL patients

CTI BioPharma Corp. and Servier today announced that the pivotal Phase III study evaluating PIXUVRI® combined with rituximab in comparison to gemcitabine combined with rituximab in patients with aggressive B-cell non-Hodgkin lymphoma did not meet its primary endpoint of improvement of progression-free survival

9 Jul 2018

Cleara Biotech creates three public-private partnerships to discover and develop new therapeutics

Cleara Biotech B.V., a Netherlands-based biopharmaceutical company, announced today the creation of three public-private partnerships to discover and develop new therapeutics.

6 Jul 2018

PMDA approves use of LYNPARZA in patients with BRCA-mutated breast cancer

AstraZeneca and Merck, known as MSD outside the United States and Canada, today announced that Japan's Pharmaceuticals and Medical Devices Agency has approved LYNPARZA tablets for use in patients with unresectable or recurrent BRCA-mutated, human epidermal growth factor receptor 2 -negative breast cancer who have received prior chemotherapy.

2 Jul 2018

New Rekovelle analysis shows AMH is robust predictor of ovarian response to fertility treatment

Ferring Pharmaceuticals announced today a new analysis of data from the Phase 3 ESTHER-1 trial showing that natural variations in anti-Müllerian hormone levels during and between a woman's menstrual cycle have no clinically relevant impact on ovarian response when using AMH to dose Rekovelle for ovarian stimulation.

2 Jul 2018

Ocular Therapeutix resubmits NDA for DEXTENZA

Ocular Therapeutix™, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, has announced the resubmission of the Company's New Drug Application to the U.S. Food and Drug Administration for its lead product candidate DEXTENZA™ 0.4mg, for the treatment of ocular pain following ophthalmic surgery.

30 Jun 2018

New medication may treat chemotherapy, radiotherapy-induced oral mucositis

Researchers from the University of Granada have developed new medication which could help to treat and prevent chemotherapy and radiotherapy-induced oral mucositis in head and neck cancer patients.

30 Jun 2018

AbbVie and Calibr collaborate to develop T-cell therapies aimed at cancer

AbbVie , a research-based global biopharmaceutical company, and Calibr, a nonprofit drug discovery division of Scripps Research, today announced a collaboration to develop T-cell therapies aimed primarily at cancer, including solid tumors.

25 Jun 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Protein Data Bank at Rutgers impacts research, education and drug discovery

When Jimmy Carter was diagnosed with end-stage metastatic melanoma in 2015, he began taking a drug developed in part using 3D molecular data.

21 Jun 2018

LabConnect collaborates with Symphony to support clinical research industry

LabConnect, LLC, a leading global provider of central laboratory and support services for biopharmaceutical, medical device and contract research organizations, and Symphony Clinical Research, a worldwide, innovative in-home clinical service provider, today announced a strategic collaboration.

20 Jun 2018

OHSU Knight Cancer Institute Director wins 2018 Tang Prize in Biopharmaceutical Science

OHSU Knight Cancer Institute Director Brian J. Druker, M.D., has been awarded the 2018 Tang Prize in Biopharmaceutical Science for his pioneering role in shaping the fields of precision medicine and targeted cancer drugs.

20 Jun 2018

New collaboration integrates Intabio's Blaze solution with Bruker's mass spectrometers

Intabio, Inc., announced today that it has entered into a collaboration with Bruker to accelerate integration of Intabio's Blaze™ solution with Bruker's high resolution mass spectrometers.

From Bruker Daltonics 14 Jun 2018

Siemens and Sartorius Stedim Biotech agree on long-term cooperation in the area of automation

The Siemens technology group and Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, have agreed on long-term cooperation in the area of automation.

From Sartorius Lab Instruments GmbH & Co. KG 13 Jun 2018

AbCellera and Denali collaborate to discover new antibodies to fight neurodegenerative diseases

AbCellera Biologics Inc. today announced the successful completion of the first phase of its collaboration with Denali Therapeutics Inc.

12 Jun 2018

Alnylam announces new positive results from Phase 1/2 study of lumasiran in patients with PH1

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Primary Hyperoxaluria Type 1.

8 Jun 2018

Biopharmaceutical News and Research

NeuroTrauma Sciences and Henry Ford join hands to advance exosome technology

Aeras announces publication of Phase 2 results of two TB vaccines

Aurinia’s Phase 2 trial evaluates voclosporin ophthalmic solution for treating dry eye syndrome

New clinical trial to evaluate virotherapy and immunotherapy combination for ovarian, colorectal cancers

Sartorius Stedim Biotech and Penn State partner to advance teaching, research in biotechnology

CTI BioPharma announces Phase III results of PIXUVRI combined with rituximab in aggressive B-cell NHL patients

Cleara Biotech creates three public-private partnerships to discover and develop new therapeutics

PMDA approves use of LYNPARZA in patients with BRCA-mutated breast cancer

New Rekovelle analysis shows AMH is robust predictor of ovarian response to fertility treatment

Ocular Therapeutix resubmits NDA for DEXTENZA

New medication may treat chemotherapy, radiotherapy-induced oral mucositis

AbbVie and Calibr collaborate to develop T-cell therapies aimed at cancer

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Protein Data Bank at Rutgers impacts research, education and drug discovery

LabConnect collaborates with Symphony to support clinical research industry

OHSU Knight Cancer Institute Director wins 2018 Tang Prize in Biopharmaceutical Science

New collaboration integrates Intabio's Blaze solution with Bruker's mass spectrometers

Siemens and Sartorius Stedim Biotech agree on long-term cooperation in the area of automation

AbCellera and Denali collaborate to discover new antibodies to fight neurodegenerative diseases

Alnylam announces new positive results from Phase 1/2 study of lumasiran in patients with PH1

Biotechnology eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News